TY - JOUR
T1 - Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer
T2 - The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions
AU - Winterhoff, Boris
AU - Kommoss, Stefan
AU - Heitz, Florian
AU - Konecny, Gottfried E.
AU - Dowdy, Sean C.
AU - Mullany, Sally A.
AU - Park-Simon, Tjoung Won
AU - Baumann, Klaus
AU - Hilpert, Felix
AU - Brucker, Sara
AU - du Bois, Andreas
AU - Schröder, Willibald
AU - Burges, Alexander
AU - Shen, Steven
AU - Wang, Jinhua
AU - Tourani, Roshan
AU - Ma, Sisi
AU - Pfisterer, Jacobus
AU - Aliferis, Constantin F.
N1 - Publisher Copyright:
(c) Connecting development of precision medicine tests to Randomized Clinical Trials enhances the robustness of computational modeling, accelerates development and validation of the precision test by 5-10 years, is highly generalizable and scalable, and should thus be considered as a high-priority design for similar precision medicine efforts.
PY - 2018
Y1 - 2018
N2 - We report recent progress in the development of a precision test for individualized use of the VEGF-A targeting drug bevacizumab for treating ovarian cancer. We discuss the discovery model stage (i.e., past feasibility modeling and before conversion to the production test). Main results: (a) Informatics modeling plays a critical role in supporting driving clinical and health economic requirements. (b) The novel computational models support the creation of a precision test with sufficient predictivity to reduce healthcare system costs up to $30 billion over 10 years, and make the use of bevacizumab affordable without loss of length or quality of life.
AB - We report recent progress in the development of a precision test for individualized use of the VEGF-A targeting drug bevacizumab for treating ovarian cancer. We discuss the discovery model stage (i.e., past feasibility modeling and before conversion to the production test). Main results: (a) Informatics modeling plays a critical role in supporting driving clinical and health economic requirements. (b) The novel computational models support the creation of a precision test with sufficient predictivity to reduce healthcare system costs up to $30 billion over 10 years, and make the use of bevacizumab affordable without loss of length or quality of life.
UR - http://www.scopus.com/inward/record.url?scp=85062378947&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062378947&partnerID=8YFLogxK
M3 - Article
C2 - 30815151
AN - SCOPUS:85062378947
SN - 1559-4076
VL - 2018
SP - 1093
EP - 1102
JO - AMIA ... Annual Symposium proceedings. AMIA Symposium
JF - AMIA ... Annual Symposium proceedings. AMIA Symposium
ER -